Abstract
Lymphomas are subdivided in Hodgkin’s disease (HD) and non-Hodgkin’s lymphomas (NHL). Essentially the medications used are of two types: monoclonal antibodies and chemotherapy. The side effects of treatment are grouped accordingly. The most commonly used treatment protocol in NHL is a combination of a monoclonal antibody with polychemotherapy. Hence, this chapter is subdivided according to these two treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smith MR. Antibodies and hematologic malignancies. Cancer J. 2008;14(3):184–90.
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12. doi:10.1182/blood-2010-11-314708.
Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol. 2012;30(suppl; abstr 3).
Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118:4585–90. doi:10.1182/blood-2011-07-365932.
Zinzani PL. Clinical experience with fludarabine in indolent non-Hodgkin’s lymphoma. Hematol J. 2004;5 Suppl 1:S38–49.
Economopoulos T, Psyrri A, Fountzilas G, Tsatalas C, Anagnostopoulos A, Papageorgiou S, et al. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. Leuk Lymphoma. 2008;49(1):68–74.
Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström’s macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J. 2004;5 Suppl 1:S50–61.
Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2012;13(8):1285–9.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, et al.; Japanese Bendamustine Lymphoma Study Group. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101(9):2059–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Wilde, S.CD. (2013). Lymphoma. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_12
Download citation
DOI: https://doi.org/10.1007/978-0-85729-787-7_12
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-786-0
Online ISBN: 978-0-85729-787-7
eBook Packages: MedicineMedicine (R0)